|
Syntekabio Inc.
Syntekabio at The BIO International Convention, June 5-8 Discover one of the South Korean artificial intelligence drug development pioneers
NEWS RELEASE BY SYNTEKABIO, INC.
New York, NY | May 31, 2023 03:30 PM Eastern Daylight Time
Syntekabio (226330.KQ), a global artificial intelligence (AI) drug discovery and development company, will exhibit at the BIO International Convention. The Convention showcases 4,000+ best and brightest biotechnology and pharma companies from 60+ countries, attracting 14,000+ attendees for intensive networking and partnership opportunities through 130+ interactive sessions across four days. Meet the Syntekabio team at our BOOTH #2785 at the BIO International Convention The Syntekabio team, led by CEO Jong-sun Jung, is looking forward to connecting with industry innovators and business leaders to build synergy through sharing expert insight and knowledge. Meet with us to learn about our latest one-stop AI drug discovery solution , and envision how Syntekabio’s supercomputing-backed AI platforms can transform your business. WHAT: The BIO International Convention (Booth #2785 near the BIO Lounge) DATE: Monday, June 5 – Thursday, June 8, 2023 TIME: 8:00 am – 5:00 pm LOCATION: Boston Convention and Exhibition Center, 415 Summer St, Boston, MA 02210 (the Seaport District of Boston, MA) NOTES: Syntekabio CEO Jongsun Jung and his team of researchers are available onsite. To arrange a meeting, contact Ellie Woo at or +1 (917) 257-4533. For general inquires on our services, email Syntekabio’s New York office at . ### About Syntekabio Syntekabio is a global artificial intelligence (AI) and big data-based drug discovery and development company, headquartered in South Korea since 2009, with its US operations bringing innovative technologies and science to create transformative medicines worldwide that are compliant with international standards to cure diseases and improve people's lives. Find out more about DeepMatcher®, NEO-ARS™, NGS-ARS™ and PGM-ARS™ at . Media Contact: Syntekabio USA Email: Tel:
The Diagram shows Docker's extension to Syntekabio's AI-powered full drug discovery service solution that support almost all areas of drug discovery & development process from Hit discovery / Lead generation, ADMET/PK to the pharmacogenomics biomarkers. It is based on Syntekabio’s powerful AI technologies (DeepMatcher®) that provides the best docking Hits/Leads through analysis of deep learning (3D-CNN) and MD simulation on targets. Docker is a virtualization software.
Contact Details Syntekabio Ellie Woo
Company Website
Syntekabio, Inc. Media Channels
Dissemination of a CORPORATE NEWS, transmitted by EQS Group. |
1648767 03-Jun-2023
